Literature DB >> 12190091

Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study.

P Sipponen1, P Ranta, T Helske, I Kääriäinen, T Mäki, A Linnala, O Suovaniemi, A Alanko, M Härkönen.   

Abstract

BACKGROUND: Helicobacter pylori infection is often diagnosed with non-endoscopic methods, such as serology or breath or antigen stool tests. These tests provide information on the presence or absence of the H. pylori gastritis only. We investigated whether atrophic gastritis can be diagnosed and typed non-endoscopically if the serum levels of pepsinogen I (S-PGI) and gastrin-17 (S-G-17) are assayed in connection with H. pylori testing.
METHODS: The present investigation is an observational case-control study comprising 100 selected dyspeptic outpatients with (cases) or without (controls) advanced (moderate or severe) atrophic gastritis. Before the blood tests, all patients underwent a diagnostic gastroscopy with multiple biopsies. The series of cases includes 56 patients. Eight had an advanced antrum limited atrophic gastritis, 13 had resected antrum (in two of whom the corpus mucosa in the stump was atrophic), and 30 had corpus-limited atrophic gastritis. Four patients had an advanced atrophic gastritis in both the antrum and corpus (multifocal atrophic gastritis), and the whole stomach was removed in one patient. Twenty of the 44 controls had a non-atrophic H. pylori gastritis. Both the antrum and corpus were normal and healthy in 24 patients. The S-PGI and S-G-17 were determined with EIA methods using monoclonal antibodies to PGI and amidated G-17. Postprandial S-G-17 (S-G-17prand) was measured 20 min after a protein-rich drink. The H. pylori antibodies were assayed with a polyclonal EIA method.
RESULTS: A low S-PGI (<25 microg/l; an empirical cut-off with best discrimination) was found in 31 of 37 patients (84%) with and in 3 of 63 patients (5%) without corpus atrophy in the biopsy specimens. A low S-G-17prand (<5 pmol/l) was found in all 8 patients with H. pylori-associated antral atrophy and in 11 of 14 patients (79%) with resected antrum but in 3 of 20 control patients (15%) with H. pylori-related non-atrophic gastritis. Median and mean values of both S-G-17prand and S-PGI decreased with increasing grade of antral and corpus atrophy, respectively. Among all patients with atrophic gastritis (multifocal atrophic gastritis, or atrophic gastritis limited to antrum or corpus) or resected stomach, 50 of 56 patients (89%; Cl 95%: 81%-97%) had a low S-PGI and/or a low S-G-17prand with positive H. pylori serology. Such low values werc found in 3 of the 44 control patients (7%; CI 95%: 0%-14%).
CONCLUSIONS: Low serum levels of G-17prand and PGI are conceivable biomarkers of atrophic antral and corpus gastritis, respectively. A low S-G-17prand is a sign of the multifocal or antrum-limited atrophic gastritis in patients infected with H. pylori.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12190091

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  34 in total

Review 1.  Biopsy assessment of drug efficacy in the gastrointestinal tract.

Authors:  Marjorie M Walker
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 2.  Current management and future strategies of gastric cancer.

Authors:  Joong Ho Lee; Kyung Min Kim; Jae-Ho Cheong; Sung Hoon Noh
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

3.  Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium.

Authors:  Francesco Di Mario; Lucas Giovanni Cavallaro; Ali Mahamat Moussa; Pietro Caruana; Roberta Merli; Andrea Maini; Simone Bertolini; Nadia Dal Bó; Massimo Rugge; Giulia Martina Cavestro; Giovanni Aragona; Mario Plebani; Angelo Franzé; Giorgio Nervi
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

4.  Gastric status and vitamin B12 levels in cardiovascular patients.

Authors:  Martijn G H van Oijen; Pentti Sipponen; Robert J F Laheij; Freek W A Verheugt; Jan B M J Jansen
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

5.  Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.

Authors:  Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali
Journal:  Biomed Rep       Date:  2017-09-20

6.  Low circulating levels of gastrin-17 in patients with Barrett's esophagus.

Authors:  Pentti Sipponen; Matti Vauhkonen; Timo Helske; Ilpo Kaariainen; Matti Harkonen
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

7.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

8.  Atrophic gastritis: deficient complex I of the respiratory chain in the mitochondria of corpus mucosal cells.

Authors:  Marju Gruno; Nadezhda Peet; Andres Tein; Riina Salupere; Meeli Sirotkina; Julio Valle; Ants Peetsalu; Enn K Seppet
Journal:  J Gastroenterol       Date:  2008-10-29       Impact factor: 7.527

9.  Possibility of non-invasive diagnosis of gastric mucosal precancerous changes.

Authors:  Victor D Pasechnikov; Sergey Z Chukov; Sergey M Kotelevets; Alexander N Mostovov; Varvara P Mernova; Maria B Polyakova
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

10.  The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology.

Authors:  Marcis Leja; Limas Kupcinskas; Konrads Funka; Agnese Sudraba; Laimas Jonaitis; Audrius Ivanauskas; Dainius Janciauskas; Gediminas Kiudelis; Han-Mo Chiu; Jaw-Town Lin
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.